• Home
  • Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Author List
Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC
Publication
Blood advances
Publication ID (Profile URL)
https://researcherprofiles.org/profile/95361622
Publication Year
2020
PubMed ID
32040554
Publication Title
Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 2020 02 11; 4(3):514-524.